In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense
Introduction
The primary objective of the National Institute of Allergy and Infectious Diseases (NIAID) In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense Program is to provide targeted screening and evaluation of potential therapeutic and prevention modalities for emerging infectious agents and bioterrorism pathogens using in vitro, small animal, and nonhuman primate models to test safety and efficacy. In vitro research and animal models are needed to ensure development and testing of vaccines, therapeutics, and diagnostics, while preclinical safety testing will be required to speed the development of new generation products.
A number of promising candidate therapies and vaccines have been identified for bioterrorism organisms/diseases; however, further development requires validated animal models in which to test these candidates. This program will provide a range of developmental resources to bring new therapies and preventive measures from the laboratory to initial clinical testing in humans.
Currently there are six parts of the program with multiple awardees in each, all contributing to the overall development effort.
back to top